Pepsi Earnings vs. ...
Health Care: Drugs
Repros Therapeutics Inc. (RPRX: NASDAQ)
$4.46 -0.06 | -1.33%
02/09/12 - 03:59 PM ET
68.27K / 58.70K
Vol / Avg. Vol:4.56 / 4.52
Open / Prev. Close:4.41 - 4.57
Today's Range:3.34 - 6.85
52 Wk Range:-6.22%
Performance YTD:TheStreet Rating:
Portfolios with RPRX
- Portfolio NameUser Type
- Contributor10 Cheap Biotech Stocks Tha...
- Contributor16 Small-Cap Stocks in Dang...
- ContributorUnder $5 Stocks at Risk of ...
- UserSUPRATRADE Top Day Trader A...
- UserMicrobanks
- UserSuzieB13 Portfolio 1
- Userjacki44 Portfolio 1
- UserRAPTOR SPRTD-23021300
- Userjgiova Portfolio 1
- Usermgorham Portfolio 1
Latest RPRX Headlines from TheStreet
- 16 Small-Cap Stocks in Danger of Delisting 03.30.11 | 07:03 am
- Repros Therapeutics Inc.(R) Reports Fourth Quarter And Year End 2010 Financial Results 03.28.11 | 09:03 am
- Repros(R) Therapeutics Commences Dosing Third Cohort In Low Dose Proellex(R) Study 03.16.11 | 09:03 am
- Repros(R) Reports Results From Completed 1 Mg Dose Cohort In Low Dose Proellex(R) Study 03.15.11 | 10:03 am
- Top Stocks Under $5 Beating the Market 02.24.11 | 06:02 am
- 5 Pharma Stocks Trading for Under $2 12.16.10 | 12:12 pm
- Under $5 Stocks at Risk of Defaulting 08.05.10 | 06:08 am
- Small-Caps Put on Nasdaq Chopping Block 06.30.10 | 08:06 am
- Genzyme's Termeer: Worst Biotech CEO of '09 11.17.09 | 12:11 pm
- Collagen Disease Breakthrough
11.16.09 | 09:11 am
Press Releases for RPRX
- Repros® Announces Dismissal Of Class Action Lawsuits - Business Wire 03.03.11 | 05:03 pm
- Repros Therapeutics® Announces Pricing Of Public Offering Of Common Stock And Warrants - Business Wire 02.03.11 | 03:02 pm
- Repros Therapeutics® Receives IRB Approval To Commence Phase IIb Study Of Androxal® In The Treatment Of Secondary Hypogonadism - Business Wire 01.03.11 | 09:01 am
- Reanalysis By Outside Statistician Shows Androxal® Provides Statistically Significant Improvement In Testosterone Levels In Men With Male Hormone Levels ≤ 250 Ng/dL - Business Wire 12.28.10 | 09:12 am
- Vaginal Delivery Of Repros’® Proellex® Bypasses First Pass Liver Effects And Achieves Greater Signals Of Efficacy At Significantly Lower Exposure - Business Wire 12.27.10 | 09:12 am
- Repros® Therapeutics Submits Data To The FDA Supporting Morning Assessment Of Testosterone For Men Treated With Androxal® As Indicative Of Average And Maximum Levels Attained - Business Wire 12.23.10 | 11:12 am
- Repros® Therapeutics Prepares To Commence Dosing In Second Cohort In Low Dose Proellex® Study - Business Wire 12.16.10 | 12:12 pm
- Repros Therapeutics Inc.® Reports Third Quarter 2010 Financial Results And Provides Corporate Update - Business Wire 11.10.10 | 06:11 am
- Repros® Announces Reverse Stock Split Effective On Nasdaq October 15, 2010 - Business Wire 10.14.10 | 08:10 pm
- FDA Grants Type B Meeting To Be Held November 8, 2010 To Discuss Phase III Protocols For Androxal® - Business Wire 09.30.10 | 06:09 am
Partner Headlines for RPRX
- Four Biotechs to Watch Early This Week - Seeking Alpha 03.06.11 | 08:03 am
- UPDATE 1-Repros submits more testosterone drug data, shrs soar - Reuters 12.23.10 | 01:12 pm
- FDA Approves Axiron - Analyst Blog - Zacks 11.24.10 | 09:11 am
- UPDATE 1-Repros to meet FDA to discuss testosterone drug trial - Reuters 09.30.10 | 08:09 am
- Repros Schedules Meeting with FDA - Analyst Blog - Zacks 08.26.10 | 10:08 am
- HEADLINE STOCKS-U.S. small/midcap stocks on the move on Aug 11 - Reuters 08.11.10 | 10:08 am
- UPDATE 1-Repros testosterone drug gets key US patent; shares up - Reuters 08.11.10 | 10:08 am
- UPDATE 3-FDA partially lifts clinical hold on Repros' drug - Reuters 06.11.10 | 11:06 am
- HEADLINE STOCKS-U.S. small/midcap stocks on the move on June 11 - Reuters 06.11.10 | 10:06 am
- HEADLINE STOCKS-U.S. small/midcap stocks to watch on June 11 - Reuters 06.11.10 | 08:06 am
